Kea Turner

Today, the U.S. Food and Drug Administration (FDA) announced that it has issued a “safe to proceed” letter to @RevMedicines, allowing the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). 💊 Expanded access is a potential pathway for patients with serious or life-threatening conditions to gain access to investigational medicines outside of a clinical trial when they are unable to participate in a clinical trial and all other appropriate treatment options have been exhausted. In response to the FDA’s letter, Revolution Medicines said that this “represents a critical step in the process of opening an EAP” and that they are “moving as quickly as possible to ensure safe and equitable access to daraxonrasib for eligible patients in the United States,” according to a statement from the company. Read Revolution Medicines’ Expanded Access Policy, including how to submit a request through a licensed treating physician and how daraxonrasib is extending survival for #pancreaticcancer patients at 🔗 pcan.at/rjul9sza.

An exciting opportunity to join @UNCSDSS! I'm currently teaching DATA 120 (and really enjoying it!); feel free to reach out if you want to discuss!

Talking about #burnout helps create culture change that leads to a better environment for all. Grateful to Dr @d_golden for sharing @IJROBP for publishing redjournal.org/article/S0360-… "practicing common humanity through public disclosure seems more important than career advancement"

No one should face cancer alone! We've partnered with Imerman Angels to provide peer-to-peer support for the head and neck cancer community.  We desperately need mentors who speak Spanish and mentors who were caregivers. Find out more about the program:  headandneck.org/peer-to-peer-p…

🚨 Many hospitals use fall prevention alarms despite limited evidence they work. @TurnerKea and colleagues had hospital staff brainstorm, rate, and sort strategies to deimplement these alarms, helping to create tailored implementation packages for each site. Read more: bit.ly/4kqQgek

@DrJoeUnger talks to us about the role of federal sponsorship in the design and conduct of cancer tx trials. More likely to: focus on rare cancers and pediatric populations, study de-escalation strategies, & involve non-tx interventional trials. ➡️huge impact! #ASCOQLTY25

We’re excited to announce that our Bachelor of Science in Nursing program is ranked fourth overall and first among public schools in U.S. News & World Report’s 2026 rankings! Read more here: go.unc.edu/j6XYt

A new report from the National Academies finds that excessive regulations and time-consuming administrative tasks are burdening the U.S. scientific enterprise. Learn more in an editorial from @ScienceMagazine: ow.ly/6agt50WZ17r

Renew NC is the state's long-term disaster recovery effort, provides assistance to repair or rebuild homes impacted by the hurricane. Homeowners in 29 #WNC counties are eligible to apply at RenewNC.org, by emailing HeleneRecovery@RenewNC.org, or calling 888-791-0207.

Thanks to the incredible advocacy of PanCAN community members, 113 bipartisan members of the House signed on to the Sewell-J Joyce pancreatic cancer FY26 Dear Colleague letter to support not only restoring the dedicated Pancreatic Cancer Research Progam (PCARP) but increasing funding to $25 million. This is a tremendous milestone – especially in a new Congress with many new members – and it shows just how powerful your voices are on Capitol Hill! Because of these actions, Congress is taking notice. 📣 Next, the House Appropriations Committee will decide whether the FY26 Department of Defense spending bill they will send to the House floor for a vote will include PCARP funding. Members of the committee are debating and making a recommendation this week. Read more about that, the actions fellow advocates are taking and how your continued actions are essential to changing the future of pancreatic cancer research ➡️ pcan.at/advocacy This is an exciting and meaningful step towards restoring dedicated pancreatic cancer research funding, but we have more work ahead to achieve this and to protect critical investments at the National Cancer Institute, the largest funder of #pancreaticcancer research in the world. 🔬🌎 Together, we can change the future of this disease. 💜

Check out my lab's latest research! #HIVOnc

This Nurses Week, we celebrate the compassion, expertise, and dedication of our nursing team. 💙 You are the heart of cancer care—and we’re so grateful for all you do to support patients and families every day.

A message from PanCAN's President & CEO, @JulieFleshman, JD, MBA: Today, the Trump administration released its FY26 budget, proposing a $17.5 billion or 37% cut to the National Institutes of Health, which includes the National Cancer Institute. At a time when pancreatic cancer is at a pivotal point for research and treatment breakthroughs, these cuts halt researchers’ work and, more importantly, progress for patients and families. Read my letter to Congress demanding that cancer research be protected and increased – because patients can’t afford to wait: pcan.at/b340vd Thank you for being part of this powerful community. Together, we will demand more, do more, deliver more, for every individual touched by this disease today and all those who will face it tomorrow.

Just published📣 In this novel study, authors explore structural inequities impacting cancer care among persons living with both HIV and cancer. Addressing health-related social needs are critical to improve outcomes: acsjournals.onlinelibrary.wiley.com/doi/abs/10.100… @OncoAlert @MoffittNews

🚨 Just released by @theNCI Annual Report to the Nation 2025: Overall Cancer Statistics Most cancers in both men and women showed decreases in mortality. The incidence rates for certain cancers including #PancreaticCancer (and bile duct cancers in women) saw increases. Details:

FY25 funding has been eliminated from the only federal program exclusively researching pancreatic cancer! Right now, members of the U.S. House of Representatives are circulating a bipartisan letter that urges key decision-makers to reinstate Pancreatic Cancer Research Program (PCARP) funding in the FY26 budget. The more representatives who sign, the stronger our message: Pancreatic cancer research urgently needs federal research investment. 📢📝 Contact your representative today and urge them to sign this critical letter in support of $25 million for PCARP! Read everything you need to know about the letter and take action today at pcan.at/advocacy. 💜

“No government—regardless of which party is in power—should dictate what private universities can teach, whom they can admit and hire, and which areas of study and inquiry they can pursue.” - President Alan Garber hrvd.me/GarberRespond3…

Funding was eliminated from the only federal program exclusively researching pancreatic cancer. But, we won’t stop fighting. This fiscal year (FY26) we’re demanding an increase to $25 million in #pancreaticcancer research funding. 💜 Right now, there's a letter circulating in the House supporting restoration of the program. Your representative needs to sign that letter — and YOUR voice matters. 📢📝Contact your member of Congress today and urge them to support research funding! Take action now ✅: p2a.co/vgOaKTI

The UNC School of Medicine was ranked Tier 1 in both Research and Primary Care in U.S. News & World Report’s 2025 “Best Graduate Schools.” UNC is one of only two medical schools in the country that are ranked Tier 1 for both categories: bit.ly/3XPVNTp

Check out our team’s work on reducing low-value fall prevention efforts: qualitysafety.bmj.com/content/early/…